PMC:7417201 / 12400-14039 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T23","span":{"begin":894,"end":898},"obj":"Body_part"},{"id":"T24","span":{"begin":974,"end":979},"obj":"Body_part"},{"id":"T25","span":{"begin":1616,"end":1631},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma49893"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T25","span":{"begin":974,"end":979},"obj":"Body_part"},{"id":"T26","span":{"begin":1616,"end":1631},"obj":"Body_part"},{"id":"T27","span":{"begin":1625,"end":1631},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T113","span":{"begin":760,"end":767},"obj":"http://purl.obolibrary.org/obo/CLO_0007929"},{"id":"T114","span":{"begin":794,"end":796},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T115","span":{"begin":814,"end":816},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T116","span":{"begin":822,"end":830},"obj":"http://purl.obolibrary.org/obo/CLO_0001040"},{"id":"T117","span":{"begin":831,"end":835},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T118","span":{"begin":831,"end":835},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T119","span":{"begin":875,"end":877},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T120","span":{"begin":974,"end":979},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T121","span":{"begin":986,"end":994},"obj":"http://purl.obolibrary.org/obo/CLO_0007926"},{"id":"T122","span":{"begin":1066,"end":1068},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T123","span":{"begin":1119,"end":1121},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T124","span":{"begin":1150,"end":1152},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T125","span":{"begin":1181,"end":1183},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T126","span":{"begin":1185,"end":1187},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T127","span":{"begin":1193,"end":1195},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T128","span":{"begin":1253,"end":1255},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T129","span":{"begin":1383,"end":1385},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T130","span":{"begin":1405,"end":1408},"obj":"http://purl.obolibrary.org/obo/CLO_0054061"},{"id":"T131","span":{"begin":1463,"end":1465},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T132","span":{"begin":1625,"end":1631},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T133","span":{"begin":1625,"end":1631},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T100","span":{"begin":0,"end":179},"obj":"Sentence"},{"id":"T101","span":{"begin":180,"end":518},"obj":"Sentence"},{"id":"T102","span":{"begin":519,"end":675},"obj":"Sentence"},{"id":"T103","span":{"begin":676,"end":690},"obj":"Sentence"},{"id":"T104","span":{"begin":691,"end":776},"obj":"Sentence"},{"id":"T105","span":{"begin":777,"end":830},"obj":"Sentence"},{"id":"T106","span":{"begin":831,"end":893},"obj":"Sentence"},{"id":"T107","span":{"begin":894,"end":973},"obj":"Sentence"},{"id":"T108","span":{"begin":974,"end":1037},"obj":"Sentence"},{"id":"T109","span":{"begin":1038,"end":1099},"obj":"Sentence"},{"id":"T110","span":{"begin":1100,"end":1158},"obj":"Sentence"},{"id":"T111","span":{"begin":1159,"end":1224},"obj":"Sentence"},{"id":"T112","span":{"begin":1225,"end":1290},"obj":"Sentence"},{"id":"T113","span":{"begin":1291,"end":1359},"obj":"Sentence"},{"id":"T114","span":{"begin":1360,"end":1418},"obj":"Sentence"},{"id":"T115","span":{"begin":1419,"end":1482},"obj":"Sentence"},{"id":"T116","span":{"begin":1483,"end":1577},"obj":"Sentence"},{"id":"T117","span":{"begin":1578,"end":1639},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":235,"end":249},"obj":"Phenotype"},{"id":"T17","span":{"begin":493,"end":505},"obj":"Phenotype"},{"id":"T18","span":{"begin":974,"end":984},"obj":"Phenotype"},{"id":"T19","span":{"begin":1100,"end":1107},"obj":"Phenotype"},{"id":"T20","span":{"begin":1225,"end":1237},"obj":"Phenotype"},{"id":"T21","span":{"begin":1291,"end":1305},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0003077"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0100749"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0003077"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"161","span":{"begin":980,"end":984},"obj":"Disease"},{"id":"162","span":{"begin":1038,"end":1046},"obj":"Disease"},{"id":"163","span":{"begin":1100,"end":1107},"obj":"Disease"},{"id":"164","span":{"begin":1225,"end":1237},"obj":"Disease"},{"id":"165","span":{"begin":1291,"end":1305},"obj":"Disease"},{"id":"167","span":{"begin":606,"end":614},"obj":"Disease"},{"id":"178","span":{"begin":260,"end":263},"obj":"Gene"},{"id":"179","span":{"begin":221,"end":229},"obj":"Species"},{"id":"180","span":{"begin":278,"end":286},"obj":"Species"},{"id":"181","span":{"begin":384,"end":392},"obj":"Species"},{"id":"182","span":{"begin":102,"end":110},"obj":"Disease"},{"id":"183","span":{"begin":235,"end":249},"obj":"Disease"},{"id":"184","span":{"begin":468,"end":476},"obj":"Disease"},{"id":"185","span":{"begin":493,"end":505},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"MESH:D010146"},{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"MESH:D003920"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"MESH:D004417"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"MESH:D006973"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"MESH:D006949"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"MESH:C000657245"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"Gene:730249"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"Tax:9606"},{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"Tax:9606"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:9606"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"MESH:C000657245"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"MESH:D006949"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"MESH:D003920"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

LitCovid-PMC-OGER-BB

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T70","span":{"begin":102,"end":110},"obj":"SP_7"}],"text":"Characteristics of overall population are also described according to stress SPECT-MPI results during COVID-19 pandemic and during the corresponding months of 2017–2019 (Table 2). In both study periods, the percentage of patients with hyperlipidemia and known CAD was higher in patients with abnormal compared with those with normal stress SPECT-MPI findings, while during 2017–2019, patients with abnormal SPECT-MPI were older (P \u003c 0.05) and had higher prevalence of diabetes (P \u003c 0.005) and hypertension (P \u003c 0.001).\nTable 2 Clinical characteristics of overall population according to MPI results during COVID-19 emergency and during 2017–2019 3-year’s corresponding months\n2020 2017–2019\nNormal (n = 79) Abnormal (n = 44) P value Normal (n = 820) Abnormal (n = 418) P value\nAge (years) 64 ± 11 64 ± 8 0.77 63 ± 11 65 ± 11 \u003c .05\nMale gender, n (%) 23 (38) 6 (43) 0.05 337 (41) 73 (17) \u003c .001\nBody mass index (kg/m2) 28.9 ± 4.9 28.1 ± 4.4 0.38 29.1 ± 6.1 27.9 ± 4.2 \u003c .001\nChest pain, n (%) 22 (38) 15 (43) 0.47 308 (38) 123 (29) \u003c .005\nDiabetes, n (%) 28 (19) 19 (36) 0.40 234 (29) 156 (37) \u003c .005\nDyspnea, n (%) 29 (22) 20 (25) 0.34 375 (46) 200 (48) 0.48\nFamily history, n (%) 36 (48) 24 (41) 0.34 446 (54) 223 (53) 0.73\nHypertension, n (%) 66 (62) 36 (76) 0.81 614 (75) 354 (85) \u003c .001\nHyperlipidemia, n (%) 54 (55) 38 (57) \u003c .05 540 (66) 317 (76) \u003c .001\nSmoking, n (%) 15 (55) 11 (57) 0.43 258 (31) 132 (32) 0.97\nKnown CAD n (%) 21 (55) 31 (57) \u003c .001 224 (27) 317 (76) \u003c .001\nValues are expressed as mean value ± standard deviation or as number (percentage) of subjects. MPI myocardial perfusion imaging, CAD coronary artery disease"}

PMC:7417201 / 12400-14039 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7417201 / 12400-14039 JSON TXT